Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer

Purpose: The introduction of PARP inhibitors (PARPis) as a treatment option for patients with high-grade serous ovarian cancer (HGSOC) modified the approach of BRCA testing worldwide. In this study, we aim to evaluate the impact of BRCA1 and BRCA2 variants on treatment response and survival outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Vendrell, Julie A., Ban, Iulian O., Solassol, Isabelle, Audran, Patricia, Cabello-Aguilar, Simon, Topart, Delphine, Lindet-Bourgeois, Clothilde, Colombo, Pierre-Emmanuel, Legouffe, Eric, D’Hondt, Véronique, Fabbro, Michel, Solassol, Jérôme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532320/
https://www.ncbi.nlm.nih.gov/pubmed/37762485
http://dx.doi.org/10.3390/ijms241814181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532320/
https://www.ncbi.nlm.nih.gov/pubmed/37762485
http://dx.doi.org/10.3390/ijms241814181

Ejemplares similares